p> and equipment 14,793 --
Additions of fixed assets (1,327,488) (8,398,701)
NET CASH USED IN INVESTING ACTIVITIES $(1,312,695) $(8,398,701)
CASH FLOWS FROM FINANCING ACTIVITIES
Issue of convertible notes -- 25,000,000
NET CASH PROVIDED BY FINANCING ACTIVITIES $-- $25,000,000
Effect of exchange rate changes on cash $531,950 $2,175,977
NET INCREASE IN CASH AND CASH EQUIVALENTS
BALANCES $5,109,985 $32,089,702
CASH AND CASH EQUIVALENTS BALANCES
AT BEGINNING OF PERIOD 19,840,812 26,992,025
CASH AND CASH EQUIVALENTS BALANCES
AT END OF PERIOD $24,950,797 $59,081,727
For more information, please contact:
CCG Elite Investor Relations
Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
'/>"/>SOURCE China-Biotics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1.
China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.2.
China-Biotics, Inc. Launches Shining Probiotics Protein Powder3.
China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility4.
China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results5.
China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site6.
China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results7.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound8.
QMed, Inc. Reports July Medicare SNP Enrollments9.
Phlo Affiliate Reports Expanded Coverage to Oregon Border10.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results11.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007